Background: To investigate the efficacy and safety of the foldable capsular vitreous body(FCVB) in the treatment of vitreoretinal diseases.
Methods: A retrospective analysis was conducted involving 20 patients (20 eyes) who underwent FCVB implantation in our hospital from September 2017 to April 2018. All the patients underwent vitrectomyand FCVB implantation, a standard three-port vitrectomy was performed, and the FCVB was implanted into the vitreous cavity. At 6 months after surgery, the visual acuity chart, Goldmann applanation tonometer, fundus photography, B-ultrasound examination, and optical coherence tomography (OCT) examination were performed on the treated eyes.The patients’ vision, intraocular pressure, retinal reattachment, and FCVB status were observed.
Results: Compared with the preoperative measurements, there was no change in visual acuity in 18 eyes at 6 months after FCVB implantation, and the difference was not significant (P=1.000); the intraocular pressure of these 18 eyes returned to normal, and the difference was significant (P=0.00001); in fundus photographyimages of these 18 eyes, B-ultrasound,OCT showed good retinal reattachment, FCVB distributed well in the vitreous cavity and evenly supported the vitreous retina and there was no obvious abnormality. The eyes were symmetrical, and the eyeball activity was normal. One patient developed eyeball atrophy after surgery, and one patient developed ocular inflammation after surgery. The condition improved after treatment.
Conclusions: FCVB is an effective and safe vitreous substitute during the 6-month implantation period and is able to maintain eye shape, intraocular pressure and good aesthetics.
Keywords: Vitreoretinal disease; vitrectomy; FCVB; intraocular pressure.